- Home
- CYH vs STOK Comparison
CYH vs STOK Comparison
Compare CYH & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- STOK
- Stock Information
- Founded
- CYH 1985
- STOK 2014
- Country
- CYH United States
- STOK United States
- Employees
- CYH N/A
- STOK N/A
- Industry
- CYH Hospital/Nursing Management
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- STOK Health Care
- Exchange
- CYH Nasdaq
- STOK Nasdaq
- Market Cap
- CYH 482.7M
- STOK 517.0M
- IPO Year
- CYH 1991
- STOK 2019
- Fundamental
- Price
- CYH $3.32
- STOK $11.58
- Analyst Decision
- CYH Hold
- STOK Strong Buy
- Analyst Count
- CYH 8
- STOK 5
- Target Price
- CYH $4.27
- STOK $24.50
- AVG Volume (30 Days)
- CYH 2.2M
- STOK 534.4K
- Earning Date
- CYH 07-23-2025
- STOK 08-06-2025
- Dividend Yield
- CYH N/A
- STOK N/A
- EPS Growth
- CYH N/A
- STOK N/A
- EPS
- CYH N/A
- STOK 0.88
- Revenue
- CYH $12,653,000,000.00
- STOK $190,908,000.00
- Revenue This Year
- CYH N/A
- STOK $378.84
- Revenue Next Year
- CYH $3.49
- STOK N/A
- P/E Ratio
- CYH N/A
- STOK $13.21
- Revenue Growth
- CYH 1.05
- STOK 2333.81
- 52 Week Low
- CYH $2.24
- STOK $5.35
- 52 Week High
- CYH $6.29
- STOK $16.15
- Technical
- Relative Strength Index (RSI)
- CYH 44.49
- STOK 67.25
- Support Level
- CYH $3.01
- STOK $11.43
- Resistance Level
- CYH $3.27
- STOK $12.25
- Average True Range (ATR)
- CYH 0.19
- STOK 0.51
- MACD
- CYH -0.07
- STOK 0.02
- Stochastic Oscillator
- CYH 31.12
- STOK 75.90
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.